Crinetics Pharmaceuticals, Inc. (CRNX) News
Track canonical SquawkNews coverage tagged to CRNX, Crinetics Pharmaceuticals, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 16 indexed stories across 7 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Crinetics, Alamar, Halozyme Report Earnings
Crinetics, Alamar, and Halozyme report better-than-expected Q2 financial results
EARNINGS | Aug 12, 2026, 12:58 PM UTC
L
CRNX - Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
CRNX - Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
EARNINGS | Aug 03, 2026, 08:05 PM UTC
L
CRNX Downgrade from Buy to Neutral W/$85.00 PT (from $55.00) at UBS
CRNX Downgrade from Buy to Neutral W/$85.00 PT (from $55.00) at UBS
EQUITY | Jul 28, 2026, 11:49 AM UTC
H
Bulls and Bears: Penguin Solutions, Draftkings, Palantir — And Stocks End Week With Solid Gains
examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories. U.S. stocks finished the week with solid gains as technology shares continued to drive the market
MACRO | Jul 11, 2026, 12:01 PM UTC
H
Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says
() -- Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather than macroeconomic factors, Morgan Stanley said in a note Tuesday. As of July 6, the NYSE Arca Pharmaceutical Index
RATES | Jul 08, 2026, 03:11 PM UTC
H
What You Missed On Wall Street On Tuesday
Stock indexes retreated amid losses for the heavyweight chip sector, making the Nasdaq the laggard, while the Dow pulled back from a record high reached in morning trading. Memory producers sank even though Samsung poste
GEOPOLITICS | Jul 07, 2026, 08:16 PM UTC
H
Crude Oil Moves Higher; Rivian Automotive Shares Plunge
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 150 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.33% to 52,882.93 while the NASDAQ fell 0.61%
RATES | Jul 07, 2026, 05:06 PM UTC
H
Midday Fly By: Wall Street starts coverage of SpaceX with bullish ratings
Stock indexes have retreated amid losses for the heavyweight chip sector and fresh deterioration in the macroeconomic backdrop. The Nasdaq was the laggard, falling over 1%, while the Dow pulled back from a record high re
MACRO | Jul 07, 2026, 03:57 PM UTC
L
Top Midday Stories: Amazon Seeking at Least $25 Billion From US Bond Sale; Fiserv Explores Sale of STAR Debit Network
() -- All three major US stock indexes were down in late-morning trading Tuesday, with the Nasdaq Composite falling 1.4%, as chip stocks sold off and SpaceX (SPCX) debuted on the Nasdaq 100. In company news, Amazon (AMZN
RATES | Jul 07, 2026, 03:43 PM UTC
H
DigitalOcean, Agios Pharmaceuticals, Kingsoft Cloud And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Nasdaq Composite falling around 1% on Tuesday. Shares of DigitalOcean Holdings Inc (NYSE: DOCN ) rose sharply after the company announced it expects a year-over-year increase in second-qu
EARNINGS | Jul 07, 2026, 02:00 PM UTC
H
Dow Gains Over 200 Points; US Trade Deficit Widens In May
U.S. stocks traded mixed this morning, with the Dow Jones index gaining more than 200 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.39% to 53,261.78 while the NASDAQ fell 0.52% to 25,985.50
RATES | Jul 07, 2026, 01:41 PM UTC
L
Sector Update: Healthcare Stocks Gain Late Afternoon
() -- Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 2.3%. The iShares Biotechnology ETF (IBB) climbed 2.1%
GEOPOLITICS | Jul 02, 2026, 07:34 PM UTC
L
Crinetics Pharmaceuticals Shares Rise After UBS Initiates Coverage
() -- Crinetics Pharmaceuticals (CRNX) shares rose 8% on Thursday after UBS initiated coverage of the stock with a buy rating and a price target of $55 per share. Trading volume stood at nearly 1.4 million shares compare
EQUITY | Jul 02, 2026, 07:04 PM UTC
L
Crinetics Pharmaceuticals shares are trading higher after UBS initiated coverage on the stock with a Buy rating and announced a $55 price ta
Crinetics Pharmaceuticals shares are trading higher after UBS initiated coverage on the stock with a Buy rating and announced a $55 price target.
EQUITY | Jul 02, 2026, 02:18 PM UTC
L
This Honeywell Aerospace Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Baird analyst Jef
EQUITY | Jul 02, 2026, 11:21 AM UTC
L
UBS Initiates Coverage On Crinetics Pharmaceuticals with Buy Rating, Announces Price Target of $55
UBS analyst Ashwani Verma initiates coverage on Crinetics Pharmaceuticals (NASDAQ: CRNX ) with a Buy rating and announces Price Target of $55.
EQUITY | Jul 02, 2026, 08:58 AM UTC